

PROGRESS & PROMISE 2014

A New Era in Inflammatory Disease Management

26–28th September 2014, Barcelona, Spain

Dear Colleague,

It is with great pleasure that we invite you to join us in Barcelona, Spain, for **Progress and Promise 2014 – A New Era in Inflammatory Disease Management**, an educational Summit designed to offer rheumatologists and dermatologists a forum to explore and discuss some of the key challenges facing them in their practice.

Over the last 10 years, advances in inflammatory disease management have meant that patients now have significant control over their disease and symptoms. However, a new era in disease management is dawning, and treatment outcomes can be further optimised through patient-centred approaches.

Through plenaries and parallel workshop sessions, we aim to share insights and experiences and discuss how advances in inflammatory disease management are affecting diagnosis and treatment in clinical practice.

To help us achieve this, we have a distinguished international faculty with extensive experience and a range of expertise across rheumatology and dermatology.

We hope you will join us in what promises to be a fascinating educational Summit, and we look forward to your participation and feedback.

Co-chairmen

Professor Bernard Combe
Montpellier University, France

Professor Frank Nestle
King's College London, UK

Professor Juan Gómez-Reino
Hospital Clínico Universitario de Santiago, Spain

Professor Lluís Puig
Hospital de la Santa Creu i Sant Pau, Spain

STEERING COMMITTEE

Hussein Abdel-Dayem, UAE

Chris Baker, Australia

Bernard Combe (Co-chair), France

Bassel El-Zorkany, Egypt

Tülin Ergun, Turkey

Pablo Gonzalez, Argentina

Walter Grassi, Italy

Juan Gómez-Reino (Co-chair), Spain

Ahmet Gul, Turkey

Robert Landewé, Netherlands

Frank Nestle (Co-chair), UK

Carle Paul, France

Lluís Puig (Co-chair), Spain

Wen-Chan Tsai, Taiwan

Tsen-Fang Tsai, Taiwan

Ricardo Machado Xavier, Brazil

The programme secretariat is applying for CME accreditation on behalf of all attending physicians.

A programme funded and sponsored by Pfizer, Inc.
All rights reserved

Date of preparation: February 2014
EU-PP 11 2014



A New Era in Inflammatory Disease Management

PROGRAMME

Friday 26th September, 18:15–19:30

Joint dermatology and rheumatology opening ceremony

- ◆ Welcome to *Progress and Promise 2014*
- ◆ The Summit programme 2014
- ◆ Immunopathology across the diseases: Is all inflammation the same?
- ◆ Novel targeted therapies: The future of inflammatory disease management?

Saturday 27th September, 09:00–18:00

Dermatology plenary programme

- ◆ Inflammatory skin diseases: Evolving management strategies through the 21st century
- ◆ Immunogenicity and biologics in psoriasis
- ◆ Psoriasis: Management of a chronic disease
- ◆ Importance of co-morbidities in the management of psoriasis
- ◆ Tailoring treatment to meet the needs of the patient
- ◆ Measuring outcomes: What matters most to the clinician and the patient?

Rheumatology plenary programme

- ◆ A new era in inflammatory disease management: Obstacles and opportunities
- ◆ Obstacles in clinical practice: Limitations of diagnostic testing
- ◆ Axial SpA: Early AS or a separate disease?
- ◆ Influencing outcomes from the outside in
- ◆ Long-term outcomes: What have we learnt from the registries?
- ◆ Personalised medicine: Can we predict therapeutic outcomes?

Sunday 28th September, 09:00–12:30

Joint plenary programme for dermatology and rheumatology

- ◆ Clinical effects of targeting intracellular signalling
- ◆ Are biosimilars the future of inflammatory disease management?
- ◆ What is the cost of innovation? What value means to patients and healthcare systems
- ◆ A new era in inflammatory disease management: Changing clinical practice

WORKSHOP SESSIONS

Saturday 27th September and Sunday 28th September

Rheumatology workshops

- ◆ When to start and how to stop biologics in RA
- ◆ Managing difficult cases in RA
- ◆ Impact beyond the joints: Detection and management of co-morbidities*
- ◆ The value of imaging in early arthritis: MRI and ultrasound
- ◆ Glucocorticoids in RA in daily practice
- ◆ Spondyloarthritis: Addressing the unmet needs
- ◆ Diagnosis and management of PsA*
- ◆ How to perform accurate diagnosis and management of non-radiographic axial SpA
- ◆ Strategies for engaging and managing patients*
- ◆ Secondary failure of TNF inhibitors*
- ◆ The economic impact of the management of inflammatory disease*

Dermatology workshops

- ◆ Practical approaches: Early diagnosis and management of spondyloarthropathies*
- ◆ Managing psoriasis in difficult clinical situations*
- ◆ Managing patients with cardiovascular co-morbidities
- ◆ Pustular and erythrodermic psoriasis
- ◆ Managing patients with co-morbidities: Immunosuppression and cancer
- ◆ Diagnosis and management of paediatric psoriasis
- ◆ Considerations for non-infectious disease management: Hepatitis and liver function
- ◆ Managing patients with psychosocial co-morbidities
- ◆ Quality of life measures in psoriasis
- ◆ Practical considerations for infection management*
- ◆ Clinical decision-making for real life situations: When guidelines are insufficient*
- ◆ Predictors of treatment response with systemic biologic agents*
- ◆ Understanding the role of health economics in the decision-making process*

*These workshops are open to both dermatologists and rheumatologists

Progress and Promise 2014 Scientific agenda

Friday 26th September

Joint dermatology and rheumatology opening ceremony

18.15	Welcome to <i>Progress and Promise</i> 2014
18.25	The Summit programme 2014
18.30	Immunopathology across the diseases: Is all inflammation the same?
19.00	Novel targeted therapies: The future of inflammatory disease management?
19.30	CLOSE AND DINNER

Saturday 27th September

Dermatology programme

Rheumatology programme

09.00	Dermatology workshop 1	09.00	A new era in inflammatory disease management: obstacles and opportunities
		09.30	Obstacles in clinical practice: limitations of diagnostic testing
10.00	Dermatology workshop 2	10.15	Axial spondyloarthritis: early ankylosing spondylitis or a separate disease?
11.00	COFFEE	11.00	COFFEE
11.30	Inflammatory skin diseases: evolving management strategies through the 21 st century	11.30	Rheumatology workshop 1
11.45	Immunogenicity and biologics in psoriasis		
12.15	Psoriasis: Management of a chronic disease	12.30	Rheumatology workshop 2
12.45	Importance of co-morbidities in the management of psoriasis		
13.15	Q&A		
13.30	LUNCH	13.30	LUNCH
14.30	Dermatology workshop 3	14.30	Influencing outcomes from the outside in
		15.05	Long-term outcomes: What have we learnt from the registries?
15.30	Dermatology workshop 4	15.40	Personalised medicine: Can we predict therapeutic outcomes?
16.30	COFFEE	16.30	COFFEE
17.00	Tailoring treatment to meet the needs of the patient	17.00	Rheumatology workshop 3
17.30	Measuring outcomes: What matters most to the clinician and the patient?		
18.00	CLOSE OF DAY TWO	18.00	CLOSE OF DAY TWO

Sunday 28th September

Joint specialty programme for dermatology and rheumatology

09.00	Workshops: Joint sessions for Dermatologists and Rheumatologists
10.00	Chairmen's welcome
10.15	Clinical effects of targeting intracellular signalling
10.45	Are biosimilars the future of inflammatory disease management?
11.15	What is the cost of innovation? What value means to patients and healthcare systems
11.45	Chairmen's close: A new era in inflammatory disease management: Changing clinical practice
12.15	CLOSE <i>Followed by lunch and departure</i>

Progress and Promise 2014

Workshop overviews

*Note that there are workshops within each specialty that will also be open to all delegates (rheumatology and dermatology) on the Sunday morning. Please review the descriptions of all workshops in order to decide which you would like to attend during this joint rheumatology and dermatology workshop session, as well as your individual specialty workshop sessions.

RHEUMATOLOGY

[When to start and how to stop biologics in rheumatoid arthritis?](#)

It is known that early and intensive treatment in rheumatoid arthritis improves patient outcomes and helps to achieve treatment targets. The decision to move to a biologic may be critical for an individual patient's chance to achieve remission or low disease activity. This session will use real cases and new data to discuss key considerations in the timing and initiation of biologic therapy, as well as the options for long-term management once patients are in remission.

[Managing difficult cases in rheumatoid arthritis](#)

Numerous complications can occur in rheumatoid arthritis making clinical management of patients difficult, such as patients with an inadequate response, refractory to treatment, or with co-morbidities that preclude the use of certain therapies. This case-study-based workshop will review considerations and therapeutic options related to the management of difficult cases of rheumatoid arthritis, and stimulate discussion around practical approaches to improved management.

[Impact beyond the joints: Detection and management of co-morbidities*](#)

Rheumatoid arthritis may be associated with a variety of co-morbidities, including cardiovascular or gastrointestinal disease, infections, osteoporosis and psychological disorders. Many of these may have a bearing on management strategies. This workshop will review common challenges encountered, including co-medication and contraindications, and will give practical guidance on the most important co-morbidities that a rheumatologist must consider.

[The value of imaging in early arthritis: MRI and ultrasound](#)

MRI and ultrasound may provide vital complementary information to assist diagnosis and management, but at present there are barriers and limitations to use, along with a lack of standardisation in recommendations. Case studies will be used to illustrate how modern imaging techniques for rheumatoid arthritis and spondyloarthritis may benefit patients, and to demonstrate the viability of the technologies in everyday clinical practice.

[Glucocorticoids in rheumatoid arthritis in daily practice](#)

Glucocorticoids are routinely used in rheumatology patients, both in monotherapy and combination. This workshop will discuss the role of glucocorticoids in modern practice, including optimal strategies for initiating and tapering treatment. There will be consideration of the extra steps and monitoring that may be required with these agents in some patient groups, and the impact that recent updates to the EULAR guidelines may have on their use in everyday practice.

[Spondyloarthritis: Addressing the unmet needs](#)

New understandings of spondyloarthritis have reinforced the heterogeneous nature of the disease, and there may be wide variation in patients seen in clinical practice. Using case studies to highlight the unmet need in axial spondyloarthritis, common clinical problems, including sub-type distinction and eligibility criteria for treatment, will be reviewed, and the dilemma of those patients who do not respond to current therapies will be discussed.

*These workshops on the Sunday are open to both dermatologists and rheumatologists

[Diagnosis and management of psoriatic arthritis*](#)

Early diagnosis of psoriatic arthritis is important for clinical outcomes, and collaboration between specialists can help catch early symptoms and achieve remission or minimal disease activity. This session will review and compare the main tools for the screening and early detection of PsA and show how these are used, with consideration for their sensitivity and specificity in everyday clinical practice. Treatment options and management strategies will also be discussed.

[How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis*](#)

The importance of early and accurate diagnosis in non-radiographic axial spondyloarthritis will be discussed, with a focus on preserving function and reducing long-term damage. Data supporting the increased effectiveness of therapy in early versus late disease will be presented, before discussing the limitations of using the ASAS classification criteria for diagnosis in clinical practice, and the potential for biologic markers. A series of patient case studies will illustrate optimal management and best practice.

[Strategies for engaging and managing patients*](#)

Specialist rheumatology nurses can play a vital role in the management of patients, offering support and education as well as undertaking routine monitoring in the clinic. This session will demonstrate the benefits that can be gained by employing a specialist nurse, from improved treatment adherence and compliance to better patient satisfaction – and the impact of these parameters on overall clinical outcomes and disease management.

[Secondary failure of TNF inhibitors*](#)

Clinical response to biologic therapies is multifactorial in nature. This session will review the possible reasons for secondary failure to TNF inhibitors, including immunogenicity as one of the possible reasons, and will discuss the importance of managing patient expectations in clinical practice. Using case studies we will explore the definition of inadequate response and discuss potential treatment strategies for optimising outcomes in these patients.

[The economic impact of the management of inflammatory disease*](#)

Uncontrolled inflammatory disease places a burden on patients, healthcare resources, and society as a whole. Early and effective treatment can significantly improve quality of life and work productivity and may even impact rates of mortality. Using case studies and real-world cost data, the cost-effectiveness and cost-benefit of biologic therapy will be reviewed, with consideration of long-term direct and indirect medical costs, as well as the wider societal impact.

DERMATOLOGY

[Managing psoriasis in difficult clinical situations*](#)

Using a series of case studies, this session will outline a variety of suggested management strategies for difficult situations commonly experienced in clinical practice. Each scenario will include a discussion of the investigations and treatment options available, the rationale behind the course of action taken, and will provide clinicians with useful key takeaway points.

[Managing patients with CV co-morbidities](#)

Several mechanisms have been proposed to explain the incidence of cardiovascular disease manifestations in psoriasis patients, including systemic inflammation, insulin resistance, dyslipidaemia and obesity, as well as environmental risk factors such as smoking and medication. Through discussion of case studies, delegates will hear about the impact of cardiovascular co-morbidities in psoriasis patients, and suggested management strategies for clinical practice.

[Pustular and erythrodermic psoriasis](#)

Pustular or erythrodermic psoriasis are severe and heterogeneous diseases. This workshop will consider the key clinical considerations for generalised and localised forms, with an examination of potential triggering

*These workshops on the Sunday are open to both dermatologists and rheumatologists

factors. Management strategies and referral pathways will be reviewed, along with the limitations of conventional topical and systemic therapies in these patients.

[Managing patients with co-morbidities: Immunosuppression and cancer](#)

Due to the chronic lifelong nature of inflammatory disease, physicians may see the co-occurrence of co-morbidities such as cancer in patients receiving systemic or biologic therapies. This workshop will review the impact of cancer in clinical practice, and discuss how to modify treatment in patients with these conditions. The need for monitoring and screening of dermatology patients will also be considered, along with the optimal interdisciplinary approach.

[Diagnosis and management of paediatric psoriasis](#)

One-third of psoriasis patients report symptoms before the age of 16. There are many challenges in managing children with psoriasis, not least the limited treatment options available and potential overlap with vaccination schedules in younger patients. This session will consider the recommendations for monitoring of paediatric patients, and review possible treatment strategies with systemic and biologic therapies.

[Considerations for non-infectious disease management: Hepatitis and liver function](#)

Liver problems are often encountered in patients in dermatological practice. In psoriasis patients some of these may be linked to aspects of the disease itself – such as non-alcoholic fatty liver disease – or associated with medications. This session will use case studies to detail how dermatologists should monitor at-risk patients and outline the modifiable risk factors, as well as reviewing the impact of liver problems on treatment strategies.

[Managing patients with psychosocial co-morbidities](#)

Psoriasis carries a heavy psychosocial burden, and dermatologists need to be aware of the risk of psychological health problems in their patients. This workshop will discuss the role dermatologists can play in identifying common risks and problems, including alcohol abuse and depression, and will describe the optimal multidisciplinary approaches to treatment.

[Practical approaches: Early diagnosis and management of spondyloarthropathies*](#)

Early diagnosis of spondyloarthropathies is essential in order to prevent functional damage and radiographic progression. Patient case studies will be used to give practical guidance on early diagnosis and management, and to highlight the importance of shared care and interdisciplinary management. Screening tools will be reviewed and compared to other methods for the early detection, diagnosis and assessment of spondyloarthropathies, such as radiography, ultrasound and MRI.

[Quality of life measures in psoriasis](#)

Diagnosis and management of psoriasis can be improved by adopting a holistic approach to patient care. This session will give an overview of the most recent advances in tools for the measurement of health-related quality of life and patient-reported outcomes. Consideration of patients as individuals is important and there may sometimes be a need to modify questionnaires for each individual patient. Examples of this will be given, along with case studies demonstrating the use of quality of life measures in clinical practice.

[Practical considerations for infection management](#)

Infections are an important consideration in clinical practice since they have an impact on treatment strategy and patient management. There are many recommendations for the monitoring of infections in patients on systemic and biologic therapies, each designed to alert clinicians to risks and allow tailored care. Through examination of case studies, this session will consider the identification of modifiable risk factors, as well as the significance of flexible treatment options in patients with infections.

*These workshops on the Sunday are open to both dermatologists and rheumatologists

Clinical decision-making for real life situations: When guidelines are insufficient?

There are many different sets of guidelines and recommendations available for the treatment of psoriasis at regional, national and international levels. Whilst these give a good overview, there may be areas where the reality of clinical practice does not match the information provided in guidelines, particularly around the management of co-morbidities or managing patient expectations or life events. This session will consider how dermatologists should manage clinical decision-making using real-life scenarios of insufficiencies or gaps in current guidelines.

Predictors of treatment response with systemic biologic agents

Predicting patient response to treatment would help improve quality of care and tailor treatment to the individual patient. Using a series of clinical case studies, this workshop will consider the role that environmental and genetic factors may play in helping to predict a response to treatment and review how these can be incorporated into treatment strategies.

Understanding the role of health economics in the decision-making process

Psoriasis and psoriatic arthritis both incur direct and indirect costs to the individual and society. This session will discuss this financial burden, taking into consideration quality of life, physical function, the ability to work, as well as disease severity and co-morbidities. Highlighting the cost of under-treatment and non-adherence, we will review the potential economic benefits of effective treatment and management.

WORKSHOPS

Please select specialty:

Rheumatology

Dermatology

Please select your preferred workshop for each session from the drop-down lists below. Workshops will be assigned based on availability; we will make every attempt to accommodate all requests.

*These workshops on the Sunday are open to both dermatologists and rheumatologists

RHEUMATOLOGY

Rheumatology workshop session 1 choice:

When to start and how to stop biologics in rheumatoid arthritis?

Managing difficult cases in rheumatoid arthritis

Impact beyond the joints: Detection and management of co-morbidities

The value of imaging in early arthritis: MRI and ultrasound

Glucocorticoids in rheumatoid arthritis in daily practice

Spondyloarthritis: Addressing the unmet needs

Diagnosis and management of psoriatic arthritis

How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis

Rheumatology workshop session 2 choice:

When to start and how to stop biologics in rheumatoid arthritis?

Managing difficult cases in rheumatoid arthritis

Impact beyond the joints: Detection and management of co-morbidities

The value of imaging in early arthritis: MRI and ultrasound

Glucocorticoids in rheumatoid arthritis in daily practice

Spondyloarthritis: Addressing the unmet needs

Strategies for engaging and managing patients

Secondary failure of TNF inhibitors

Rheumatology workshop session 3 choice:

When to start and how to stop biologics in rheumatoid arthritis?

Managing difficult cases in rheumatoid arthritis

The economic impact of the management of inflammatory disease

How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis

Glucocorticoids in rheumatoid arthritis in daily practice

Spondyloarthritis: Addressing the unmet needs

Diagnosis and management of psoriatic arthritis

Secondary failure of TNF inhibitors

Joint workshop session choice:

Practical approaches: Early diagnosis and management of spondyloarthropathies*

Managing psoriasis in difficult clinical situations*

Impact beyond the joints: Detection and management of co-morbidities*

How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis*

The economic impact of the management of inflammatory disease*

Strategies for engaging and managing patients*

Diagnosis and management of psoriatic arthritis*

Secondary failure of TNF inhibitors*

Backup workshop choice:

When to start and how to stop biologics in rheumatoid arthritis?

Managing difficult cases in rheumatoid arthritis

Impact beyond the joints: Detection and management of co-morbidities
The value of imaging in early arthritis: MRI and ultrasound
Glucocorticoids in rheumatoid arthritis in daily practice
Spondyloarthritis: Addressing the unmet needs
Diagnosis and management of psoriatic arthritis
How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis
Strategies for engaging and managing patients
Secondary failure of TNF inhibitors
The economic impact of the management of inflammatory disease
Practical approaches: Early diagnosis and management of spondyloarthropathies
Managing psoriasis in difficult clinical situations

DERMATOLOGY

Dermatology workshop session 1 choice:

Managing psoriasis in difficult clinical situations
Managing patients with CV co-morbidities
Pustular and erythrodermic psoriasis
Managing patients with co-morbidities: Immunosuppression and cancer
Diagnosis and management of paediatric psoriasis
Considerations for non-infectious disease management: Hepatitis and liver function

Dermatology workshop session 2 choice:

Managing psoriasis in difficult clinical situations
Managing patients with CV co-morbidities
Pustular and erythrodermic psoriasis
Managing patients with co-morbidities: Immunosuppression and cancer
Diagnosis and management of paediatric psoriasis
Considerations for non-infectious disease management: Hepatitis and liver function

Dermatology workshop session 3 choice:

Managing patients with psychosocial co-morbidities
Practical approaches: Early diagnosis and management of spondyloarthropathies
Quality of life measures in psoriasis
Practical considerations for infection management
Clinical decision-making for real life situations: When guidelines are insufficient?
Predictors of treatment response with systemic biologic agents

Dermatology workshop session 4 choice:

Understanding the role of health economics in the decision-making process
Practical approaches: Early diagnosis and management of spondyloarthropathies
Quality of life measures in psoriasis
Practical considerations for infection management
Clinical decision-making for real life situations: When guidelines are insufficient?
Predictors of treatment response with systemic biologic agents

Dermatologists joint workshop session choice:

Practical approaches: Early diagnosis and management of spondyloarthropathies*
Managing psoriasis in difficult clinical situations*
Impact beyond the joints: Detection and management of co-morbidities*
How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis*
The economic impact of the management of inflammatory disease*
Strategies for engaging and managing patients*

Diagnosis and management of psoriatic arthritis*
Secondary failure of TNF inhibitors*

Backup workshop choice:

Managing psoriasis in difficult clinical situations
Managing patients with CV co-morbidities
Pustular and erythrodermic psoriasis
Managing patients with co-morbidities: Immunosuppression and cancer
Diagnosis and management of paediatric psoriasis
Considerations for non-infectious disease management: Hepatitis and liver function
Managing patients with psychosocial co-morbidities
Practical approaches: Early diagnosis and management of spondyloarthropathies
Quality of life measures in psoriasis
Practical considerations for infection management
Clinical decision-making for real life situations: When guidelines are insufficient?
Predictors of treatment response with systemic biologic agents
Impact beyond the joints: Detection and management of co-morbidities
How to perform accurate diagnosis and management of non-radiographic axial spondyloarthritis
The economic impact of the management of inflammatory disease
Strategies for engaging and managing patients
Diagnosis and management of psoriatic arthritis
Secondary failure of TNF inhibitors

MEETING LOGISTICS

- **Meeting Location:** The meeting will take place at the Gran Via Conference Center in Barcelona, Spain
- **Hotel:** The cost of the hotel accommodations (room & tax) for the evenings of September 26th and 27th is included in the delegate rate and will be paid directly by Pfizer. Please advise your delegates to be prepared to present a credit card to the hotel front desk clerk upon their arrival to cover incidentals (phone calls, room service, etc.).

If requested, reservations for additional room nights will be made on the delegates behalf and the cost billed back to your respective market. Please include the reason for the extended stay and the dates in the Rooming Notes section and confirm that the additional expense is approved and the additional room nights are compliant with your local travel policy.

You will be advised of hotel assignment approximately 2 weeks prior to the meeting.

- **Air Travel:** Book travel for your delegates using your local travel agency and provide the flight information requested in the group registration spreadsheet.
- **Ground Transportation:** Ground transportation between the airport and hotel in Barcelona will be arranged based on the flight information provided when you register your delegates. Ground transportation between the hotel and conference center, and to the off-site dinners will also be provided.
- **Meal Functions:** Offsite country dinners are planned for the evenings of Friday, 26-September and Saturday, 27-September. The restaurant options will be emailed to you at a later date along with a link to website where you will be able to make your dinner reservation. Transportation, if needed, will be provided for everyone.

Pfizer policies and PhRMA guidelines prohibit non-meeting participants (spouses, companions and guests) from attending Pfizer sponsored meetings and/or events.

GROUP REGISTRATION

- To register your physician delegates, populate the required information to attached the Progress and Promise 2014 Delegate Manual Registration Form. This is the form that must be completed for manual registration, so please be sure to use form. *All fields must be completed in order for the registration to be complete.*
- The deadline to register your delegates is Monday, 4 August, 2014.
- Do not register Faculty as they will receive an individual registration for this meeting.
- This registration is for HCP physician delegates only. All Pfizer colleagues will receive an individual registration link to register themselves.
- You will need to select the workshops for your HCP Physician Delegates. If they are a Rheumatologist indicate their workshops in the Rheumatology fields and then mark in the Dermatology fields "not participating in workshops". If they are a Dermatologist indicate their workshops in the Dermatology fields and then mark in the Rheumatology fields "not participating in workshops".

For questions regarding registration and travel please send email to 2014ProgressandPromise@pfizer.com.